Summary
No FDA prescribing information excerpts provided for Japan approval status, PMDA listing attributes, or brand attribution; therefore the provided claims cannot be verified against the supplied label content.
Category Scores
Accurate Statements
Unsupported Statements
Elaprase (idursulfase) has been granted marketing approval in Japan.
Not supported or addressed by the supplied FDA label excerpts (which cover dosing/administration and warnings/precautions, not Japan regulatory status).
In Japan, Elaprase is approved as a therapy for Hunter syndrome (mucopolysaccharidosis II, MPS II).
The supplied FDA excerpts do not include Japan-specific approval/indication statements.
In Japan, Elaprase is approved for treatment of Hunter syndrome (MPS II).
The supplied FDA excerpts do not include Japan-specific approval/indication statements.
In Japan, the product listing attributes Elaprase to Shire.
The supplied FDA excerpts do not include Japan product listing/attribution details.
Elaprase appears under commercial product details in Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) product information.
The supplied FDA excerpts do not include PMDA listing/location details.
Contradictions
Important Omissions
Japan regulatory approval, PMDA listing details, and product attribution information are not contained in the provided FDA label excerpts, so they cannot be assessed for accuracy.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Claims are about Japan approval/listing attribution rather than dosing, contraindications, warnings, administration, or safety-related instructions; no direct unsafe dosing or contraindication error can be inferred from the provided claims given the label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Alignable
Primary Issue
The evaluated claims concern Japan regulatory approval/PMDA listing details, but the provided FDA label excerpts do not contain information needed to verify those claims.
Suggested Improvement
Provide the exact FDA label sections that state approval indications/dosing (including full Indications and Usage and Regulatory/Marketing information if present) or provide the relevant official non-FDA Japan sources; otherwise limit the claims to what is explicitly contained in the supplied FDA label excerpts.